{"id":"https://openalex.org/W3139515949","doi":"https://doi.org/10.1093/rheumatology/keab294","title":"Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study","display_name":"Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study","publication_year":2021,"publication_date":"2021-03-19","ids":{"openalex":"https://openalex.org/W3139515949","doi":"https://doi.org/10.1093/rheumatology/keab294","mag":"3139515949","pmid":"https://pubmed.ncbi.nlm.nih.gov/33752237"},"language":"en","primary_location":{"id":"doi:10.1093/rheumatology/keab294","doi":"https://doi.org/10.1093/rheumatology/keab294","is_oa":false,"landing_page_url":"https://doi.org/10.1093/rheumatology/keab294","pdf_url":null,"source":{"id":"https://openalex.org/S183989336","display_name":"Lara D. Veeken","issn_l":"1462-0324","issn":["1462-0324","1462-0332"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Rheumatology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5009688412","display_name":"Rishi J. Desai","orcid":"https://orcid.org/0000-0003-0299-7273","observed_orcids":["https://orcid.org/0000-0003-0299-7273"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Rishi J Desai","raw_affiliation_strings":["Department of Medicine, Division of Pharmacoepidemiology and Pharmacoeconomics, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Division of Pharmacoepidemiology and Pharmacoeconomics, Boston, MA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102890723","display_name":"Ajinkya M Pawar","orcid":"https://orcid.org/0000-0002-8585-9505","observed_orcids":["https://orcid.org/0000-0002-8585-9505"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ajinkya Pawar","raw_affiliation_strings":["Department of Medicine, Division of Pharmacoepidemiology and Pharmacoeconomics, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Division of Pharmacoepidemiology and Pharmacoeconomics, Boston, MA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049404652","display_name":"Farzin Khosrow\u2010Khavar","orcid":"https://orcid.org/0000-0003-3636-8918","observed_orcids":["https://orcid.org/0000-0003-3636-8918"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Farzin Khosrow-Khavar","raw_affiliation_strings":["Department of Medicine, Division of Pharmacoepidemiology and Pharmacoeconomics, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Division of Pharmacoepidemiology and Pharmacoeconomics, Boston, MA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047117557","display_name":"Michael E. Weinblatt","orcid":"https://orcid.org/0000-0001-5215-5512","observed_orcids":["https://orcid.org/0000-0001-5215-5512"]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael E Weinblatt","raw_affiliation_strings":["Division of Rheumatology, Inflammation, and Immunity, Brigham and Women\u2019s Hospital & Harvard Medical School, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Rheumatology, Inflammation, and Immunity, Brigham and Women\u2019s Hospital & Harvard Medical School, Boston, MA, USA","institution_ids":["https://openalex.org/I1283280774","https://openalex.org/I136199984"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5100615887","display_name":"Seoyoung C. Kim","orcid":"https://orcid.org/0000-0002-2517-3579","observed_orcids":["https://orcid.org/0000-0002-2517-3579"]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Seoyoung C Kim","raw_affiliation_strings":["Department of Medicine, Division of Pharmacoepidemiology and Pharmacoeconomics, Boston, MA, USA","Division of Rheumatology, Inflammation, and Immunity, Brigham and Women\u2019s Hospital & Harvard Medical School, Boston, MA, USA"],"raw_orcid":"https://orcid.org/0000-0002-2517-3579","affiliations":[{"raw_affiliation_string":"Department of Medicine, Division of Pharmacoepidemiology and Pharmacoeconomics, Boston, MA, USA","institution_ids":[]},{"raw_affiliation_string":"Division of Rheumatology, Inflammation, and Immunity, Brigham and Women\u2019s Hospital & Harvard Medical School, Boston, MA, USA","institution_ids":["https://openalex.org/I1283280774","https://openalex.org/I136199984"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5009688412"],"corresponding_institution_ids":[],"apc_list":{"value":2817,"currency":"GBP","value_usd":4225},"apc_paid":null,"fwci":10.1567,"has_fulltext":false,"cited_by_count":72,"citation_normalized_percentile":{"value":0.99039385,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":97,"max":100},"biblio":{"volume":"61","issue":"1","first_page":"121","last_page":"130"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":0.9609000086784363,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":0.9609000086784363,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10285","display_name":"Venous Thromboembolism Diagnosis and Management","score":0.03700000047683716,"subfield":{"id":"https://openalex.org/subfields/2724","display_name":"Internal Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tofacitinib","display_name":"tofacitinib","score":0.9419999718666077},{"id":"https://openalex.org/keywords/venous-thromboembolism","display_name":"venous thromboembolism","score":0.9900000095367432},{"id":"https://openalex.org/keywords/rheumatoid-arthritis","display_name":"rheumatoid arthritis","score":0.9810000061988831},{"id":"https://openalex.org/keywords/tnf-alpha-inhibitors","display_name":"TNF-alpha inhibitors","score":0.9879999756813049},{"id":"https://openalex.org/keywords/pulmonary-embolism","display_name":"pulmonary embolism","score":0.9290000200271606},{"id":"https://openalex.org/keywords/deep-vein-thrombosis","display_name":"deep vein thrombosis","score":1.0},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.6589999794960022},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.531000018119812},{"id":"https://openalex.org/keywords/propensity-score-weighting","display_name":"propensity score weighting","score":0.5580000281333923},{"id":"https://openalex.org/keywords/incidence-rates","display_name":"incidence rates","score":0.4090000092983246},{"id":"https://openalex.org/keywords/biological-therapy","display_name":"biologic therapy","score":0.5329999923706055},{"id":"https://openalex.org/keywords/medicare-claims-data","display_name":"Medicare claims data","score":0.49300000071525574},{"id":"https://openalex.org/keywords/marketscan","display_name":"MarketScan","score":0.6930000185966492},{"id":"https://openalex.org/keywords/jak-inhibitors","display_name":"JAK inhibitors","score":0.5019999742507935},{"id":"https://openalex.org/keywords/propensity-score-stratification","display_name":"propensity score stratification","score":0.4020000100135803}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9500488042831421},{"id":"https://openalex.org/C2778886723","wikidata":"https://www.wikidata.org/wiki/Q3530324","display_name":"Tofacitinib","level":3,"score":0.8808530569076538},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6512838006019592},{"id":"https://openalex.org/C17923572","wikidata":"https://www.wikidata.org/wiki/Q7250160","display_name":"Propensity score matching","level":2,"score":0.6203898191452026},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.6094195246696472},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5014634132385254},{"id":"https://openalex.org/C2777575956","wikidata":"https://www.wikidata.org/wiki/Q187255","display_name":"Rheumatoid arthritis","level":2,"score":0.4882335960865021},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.45359107851982117},{"id":"https://openalex.org/C50382708","wikidata":"https://www.wikidata.org/wiki/Q223218","display_name":"Proportional hazards model","level":2,"score":0.44674432277679443},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.3313502371311188},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000075242","descriptor_name":"Janus Kinase Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D001172","descriptor_name":"Arthritis, Rheumatoid","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010880","descriptor_name":"Piperidines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D015331","descriptor_name":"Cohort Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D054556","descriptor_name":"Venous Thromboembolism","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1093/rheumatology/keab294","doi":"https://doi.org/10.1093/rheumatology/keab294","is_oa":false,"landing_page_url":"https://doi.org/10.1093/rheumatology/keab294","pdf_url":null,"source":{"id":"https://openalex.org/S183989336","display_name":"Lara D. Veeken","issn_l":"1462-0324","issn":["1462-0324","1462-0332"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Rheumatology","raw_type":"journal-article"},{"id":"pmid:33752237","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/33752237","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Rheumatology (Oxford, England)","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"sustainable_development_goals_aurora":[],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":24,"referenced_works":["https://openalex.org/W1534350202","https://openalex.org/W1572727384","https://openalex.org/W1968839273","https://openalex.org/W2049491523","https://openalex.org/W2087018232","https://openalex.org/W2142004396","https://openalex.org/W2164595809","https://openalex.org/W2169097752","https://openalex.org/W2559506670","https://openalex.org/W2736544464","https://openalex.org/W2775284703","https://openalex.org/W2886056851","https://openalex.org/W2905169896","https://openalex.org/W2945228415","https://openalex.org/W2974844397","https://openalex.org/W2982188023","https://openalex.org/W3033792883","https://openalex.org/W3035616984","https://openalex.org/W3036169639","https://openalex.org/W3042360303","https://openalex.org/W3047229059","https://openalex.org/W3123452764","https://openalex.org/W4247851911","https://openalex.org/W6680982027"],"related_works":["https://openalex.org/W2905169896","https://openalex.org/W4392816762","https://openalex.org/W4415060375","https://openalex.org/W2908381904","https://openalex.org/W4301150362","https://openalex.org/W4307988519","https://openalex.org/W2945734859","https://openalex.org/W4301283258","https://openalex.org/W3047229059","https://openalex.org/W2808240072"],"abstract_inverted_index":{"OBJECTIVE:":[0],"To":[1],"evaluate":[2],"the":[3,187],"risk":[4,188,235],"of":[5,28,115,133,189,204,218,236],"venous":[6],"thromboembolism":[7],"(VTE)":[8],"with":[9,12,16,107,198],"tofacitinib":[10,22,32,140,175,192,224,239],"compared":[11],"TNFis":[13,194,241],"in":[14,157,164,172,186,195,215,242],"patients":[15,20,124,222],"RA.":[17],"METHODS:":[18],"RA":[19,123,221,243],"initiating":[21,223],"or":[23,31,49,62,77,225],"a":[24,199,216,226],"TNFi":[25],"without":[26],"use":[27],"any":[29,33,196],"biologic":[30],"time":[34],"prior":[35],"were":[36,103,125,139,151],"identified":[37,70,126],"from":[38,127],"IBM":[39],"'MarketScan'":[40],"(2012-18),":[41],"Medicare":[42,129],"(parts":[43],"A,":[44],"B":[45],"and":[46,53,90,120,130,137,154,161,166,169,176,193],"D,":[47],"2012-17)":[48],"'Optum'":[50],"Clinformatics":[51],"(2012-19)":[52],"followed":[54],"until":[55],"treatment":[56,58],"discontinuation,":[57],"switch,":[59],"insurance":[60],"disenrollment":[61],"administrative":[63],"censoring.":[64],"The":[65,142],"primary":[66],"outcome,":[67],"VTE,":[68],"was":[69],"using":[71],"inpatient":[72],"claims":[73],"for":[74,95,174,232,238],"pulmonary":[75],"embolism":[76],"deep":[78],"vein":[79],"thrombosis.":[80],"A":[81,113],"Cox":[82],"proportional":[83],"hazards":[84],"model":[85],"provided":[86],"hazard":[87],"ratio":[88],"(HR)":[89],"95%":[91],"CIs":[92],"after":[93],"accounting":[94],"confounding":[96],"through":[97],"propensity":[98],"score":[99],"fine-stratification":[100],"weighting.":[101],"HRs":[102,181],"pooled":[104,200],"across":[105],"databases":[106],"inverse":[108],"variance":[109],"meta-analytic":[110],"method.":[111],"RESULTS:":[112],"total":[114,217],"42":[116],"201,":[117],"25":[118],"078":[119],"20":[121],"374":[122],"MarketScan,":[128,158],"Optum,":[131],"respectively,":[132],"whom":[134],"7.1,":[135],"7.1":[136],"9.7%":[138],"initiators.":[141],"crude":[143],"incidence":[144],"rates":[145],"per":[146,213],"100":[147],"person-years":[148],"(95%":[149,202],"CI)":[150,203],"0.42":[152],"(0.20-0.77)":[153],"0.35":[155],"(0.29-0.42)":[156],"1.18":[159],"(0.68-1.92)":[160],"0.83":[162],"(0.71-0.97)":[163],"Medicare,":[165],"0.19":[167],"(0.04-0.57)":[168],"0.34":[170],"(0.26-0.44)":[171],"Optum":[173],"TNFis,":[177],"respectively.":[178],"Propensity":[179],"score-weighted":[180],"showed":[182],"no":[183,230],"significant":[184],"differences":[185],"VTE":[190,209,237],"between":[191],"database":[197],"HR":[201],"1.13":[205],"(0.77-1.65).":[206],"CONCLUSION:":[207],"Overall,":[208],"occurred":[210],"infrequently":[211],"(<1":[212],"100)":[214],"87":[219],"653":[220],"TNFi.":[227],"We":[228],"observed":[229],"evidence":[231],"an":[233],"increased":[234],"vs":[240],"patients.":[244]},"counts_by_year":[{"year":2026,"cited_by_count":7},{"year":2025,"cited_by_count":11},{"year":2024,"cited_by_count":12},{"year":2023,"cited_by_count":13},{"year":2022,"cited_by_count":24},{"year":2021,"cited_by_count":5}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2021-03-29T00:00:00"}